Format

Send to

Choose Destination
See comment in PubMed Commons below
N Engl J Med. 2006 Apr 27;354(17):1807-12.

Variant of hepatitis B virus with primary resistance to adefovir.

Author information

  • 1Institute of Medical Microbiology and Immunology and the Department of Medicine I, University of Bonn, Bonn, Germany.

Abstract

The reverse-transcriptase inhibitor lamivudine (Zeffix, GlaxoSmithKline) is often used to treat chronic infection with hepatitis B virus (HBV) until resistance develops. Treatment may then be switched to the reverse-transcriptase inhibitor adefovir (Hepsera, Gilead), which has a lower frequency of resistance. Here, we describe three cases of primary adefovir resistance that were sensitive to tenofovir (Viread, Gilead). All three cases involved a rare HBV variant with a valine at position 233 of the reverse-transcriptase domain instead of isoleucine (rtI233V), as in the wild-type virus. This HBV variant also displayed resistance to adefovir and sensitivity to tenofovir in vitro.

PMID:
16641397
DOI:
10.1056/NEJMoa051214
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center